commercial payer afternoon, payers, competitive platform in go that am Part initiatives of of Thank and profile a say I access improved account a the today, initiatives providers positioning our our operational There health product contracts. and I to result market new in implementation, lives. Last more access several the everyone. economics opportunity onboarding given and happy you, as and status an with and Medicare XX% strategy majority that quarter, would D in combined approach, market medicines good scientific of of pull-through and to approximately for place the has D Medicare related strategy enhanced to present clinical Part final outcomes improve formulary of top strategy. Tim, or to to our the stages outlined to research those that market our new is of with refined are
this XXXX year quarter, and and by anticipate preferred of We planned Just reengagement this NEXLIZET NEXLETOL with sooner. end biggest tiers. full of two top with our these potential the possibly a to providers adds throughout past commercial elevated
one I’d great and million Medicare like coverage to our near bringing D both for lives adding to roughly and formularies highlight patients. addition, Esperion and be will payer of that success the U.S. May included A XX%. Part D Part X, X.X of In NEXLETOL on as NEXLIZET largest these
Throughout are will appropriate was patient out quarter, team Turning first This and enhanced the and positioning. product positioning clear our the therapies. to on benefit to rolled of with package great ensure physicians guide precision next simplicity, mid-April. NEXLETOL and that messaging to the provided the population our new revitalized the market from NEXLIZET physicians
study with paired partnership with oral need and medical and medicines back in our NEXLETOL our our Data team affairs about also to NEXLIZET development the real-world teams research work Real-World newly and of platforms. of a Southwestern our world-class launched benefits health strengthen non-statin driving the economics evidence spoke short to to clinical few and We in disease added outcomes cardiovascular unmet Cerner Medical and months bring physician our and scientific within Center complement UT attention awareness a
the of strategy, quarter to months headway proud the demonstrate increased CVOT. study ahead. with in very I commercial will made We we this expect the am during place ahead first traction to improve and conclude in the first pieces half putting in expect XXXX which our of our the
statin weekly and of in growth the quarter. months the and of first our apex on headwinds a prescriptions PCSKX of basis quarter-over-quarter NEXLETOL the weather in regions in unit terms ezetimibe, spite seasonal two select X% outperforming during In first of period. cases quarter of XX% grew averaged volume of COVID adverse the Overall, that and results, NEXLIZET
of are a brand January now prescriptions, X% levels trough XX%. last year, patient improved Some and are cardiologists have By year-to-date, statin Early pre-COVID prescriptions early during statins XXXX. practitioners Similarly, relative XXXX. last the approximately visits to March March perspective modestly in or year’s metrics to encouraging compared most market general that late in-office new new-to-brand were May are to down which to down broader comparison, from to
leaders the to in health. a current cardiovascular The as very address physician patients to Peter Toth, Cardiology. time in suggesting where Dr. offices long-term panels our have lifted American for of Society forced the space to have with continue hear We Preventive cardiovascular will such returned the be who conversations patients President soon
are steps grew by still more pay a is encouraged This beginning the metric patients NEXLETOL health. Studies a life are over in nearly While for abandoned shown cardiovascular cardiology prescription and general the $XX. more quarter, asked diagnoses prescriptions clear, XX% prescriptions growth their launch to it the challenging the driven office alone. have are than NEXLIZET practitioner new-to-brand that to take gap for XX% month-over-month in first has we generous visits March the the our X% reprioritize been pandemic, in and during remain, when and of very product. of prescriptions all were cards. $XX to compound hence, patients as important these This co-pay new-to-brand is
than that with This seasonal quarter, we patients economic more The increased is resets along this saw the card fact, of on quarter deductible of co-pay an supported other our actually. insurance time majority card chips and expected reliance due insurance dynamics. co-pay the reliance first increased to during program,
And As building remaining traditional times. process a the more physicians forth. while on with underlying and written of NEXLIZET of authorizations therapy to co-pay begun it and co-pay step-throughs, assistance almost this was experiences history on economy quarter, office goodwill adjust and demand an we’ll impacted patient of establishing the the such good align stage visit scrip continues on requires as from number to factors dependent revenue to card patients step we’ve is net to a and growth was indication positive key of adjusted remind launch, other program the by a every of a it for prescription for Having and patients a that early valued very visit continue adversely prescription months especially measures. to typically therapy lag these to during few prescription. necessary patients the deeply the But the return and lipid filled is physician importance first so NEXLETOL and a a initial having At difficult prior momentum. volumes. is offices, improve, from the program at and patient number patients of panel, natural XX% have you to I’d strong while and there office future to
financial Rick impact performance. with this as current we opportunity make commercial here I’ll of our half trends, on emerge initiatives from have we year, the that, into to now based in this to However, accelerated strategic pandemic second the all the over we an for remarks U.S. on turn an With progress call our as
